Antiplatelet Drugs: Aspirin, Clopidogrel & Friends
A tablet older than most countries' pension systems — plain aspirin — prevents millions of heart attacks and strokes a year, and it does it by permanently crippling a cell that has no nucleus and can never repair itself. Understanding that one trick unlocks the whole family of clot-preventing drugs used after every heart attack and stent. But their power to stop clots is also their danger: they make you bleed.
After a heart attack and a stent, a patient leaves hospital on two little pills to be taken together every day — aspirin and a second antiplatelet. Their job is to stop platelets from clumping and forming a fresh clot on the new stent, which could block it and cause another heart attack. It's a delicate balance: enough platelet suppression to prevent a clot, but not so much that the patient bleeds dangerously. To understand that balancing act, we start with how a platelet forms a clot — and how aspirin disables it for good.
Aspirin: permanent platelet sabotage
Platelets form the first plug in arterial clots. When an artery's lining is injured — as when a plaque ruptures in a heart attack — platelets rush to plug the gap, activating and clumping together. A key signal that makes them clump is thromboxane A2, which platelets produce using an enzyme called COX-1. Aspirin permanently blocks COX-1, so the platelet can no longer make thromboxane — and because a platelet has no nucleus, it can't manufacture new enzyme, so it stays disabled for its entire lifespan (about 7–10 days). That's why a small daily aspirin gives lasting protection, and why its effect lingers for days after the last dose. Its main uses are treating and preventing heart attacks and strokes; its main harm is bleeding, especially stomach ulcers and bleeds.
The rest of the family
The P2Y12 inhibitors block a different platelet-activating signal, the ADP receptor. Clopidogrel is the classic — but it's a prodrug that must be activated by the liver enzyme CYP2C19, so 'poor metabolizers' (from the metabolism articles) get less protection from it. Prasugrel and ticagrelor are more reliable alternatives (ticagrelor is reversible and not a prodrug). After a heart attack or stent, one of these is combined with aspirin as 'dual antiplatelet therapy' — hitting two different platelet signals at once for stronger protection. For the highest-risk moments, such as during a stenting procedure, the powerful intravenous GPIIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) block the very final step of platelet clumping. Across all of them, the trade-off is the same: more clot prevention means more bleeding risk.
Aspirin's irreversibility is its superpower AND its problem. Because it disables platelets for their whole life, a once-daily low dose keeps ALL new platelets suppressed — elegant and long-lasting. But it also means the effect can't be quickly switched off: if a patient on aspirin needs urgent surgery or bleeds, you can't 'reverse' it, and only transfusing fresh platelets restores clotting. The same permanence that makes it a great preventive makes it a liability in a bleeding emergency.
- Antiplatelets prevent arterial clots (heart attack, stroke); their main risk is bleeding.
- Aspirin irreversibly blocks COX-1 → no thromboxane → platelet disabled for its whole life.
- P2Y12 inhibitors (clopidogrel—a CYP2C19 prodrug, prasugrel, ticagrelor) block the ADP receptor.
- Dual antiplatelet therapy (aspirin + a P2Y12 inhibitor) is used after ACS and stents.
- GPIIb/IIIa inhibitors block the final aggregation step (IV, during PCI).
- Expecting to reverse aspirin quickly. It's irreversible — only platelet transfusion helps.
- Forgetting clopidogrel is a prodrug — poor CYP2C19 metabolizers get less effect.
- Ignoring bleeding risk, especially GI, and forgetting stomach protection when needed.
- Confusing antiplatelets (arterial clots) with anticoagulants (venous clots) — different jobs.
How does aspirin prevent clots?
- Antiplatelets prevent arterial clots; aspirin irreversibly blocks COX-1 (no thromboxane) for the platelet's life.
- P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) block the ADP receptor; clopidogrel is a CYP2C19 prodrug.
- Dual antiplatelet therapy (aspirin + P2Y12) follows ACS/stents; GPIIb/IIIa inhibitors hit the final step.
- The dominant risk is bleeding; aspirin can't be quickly reversed.
- Katzung BG. Basic & Clinical Pharmacology — Drugs Used in Disorders of Coagulation (antiplatelets).
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Antiplatelet drugs.
- Rang HP, Dale MM, et al. Rang & Dale's Pharmacology — Haemostasis & thrombosis: antiplatelet agents.
- ACC/AHA & ESC guidelines — Antiplatelet therapy & dual antiplatelet therapy.
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — Antiplatelet drugs.
